CRISPR Therapeutics AG (CRSP) Other Gross PP&E Adjustments (2016 - 2025)
Historic Other Gross PP&E Adjustments for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $68.8 million.
- CRISPR Therapeutics AG's Other Gross PP&E Adjustments rose 1941.31% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 1941.31%. This contributed to the annual value of $59.8 million for FY2024, which is 8105.27% up from last year.
- Per CRISPR Therapeutics AG's latest filing, its Other Gross PP&E Adjustments stood at $68.8 million for Q3 2025, which was up 1941.31% from $65.3 million recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's Other Gross PP&E Adjustments registered a high of $68.8 million during Q3 2025, and its lowest value of -$79.5 million during Q2 2021.
- In the last 5 years, CRISPR Therapeutics AG's Other Gross PP&E Adjustments had a median value of $43.7 million in 2023 and averaged $31.2 million.
- Over the last 5 years, CRISPR Therapeutics AG's Other Gross PP&E Adjustments had its largest YoY gain of 51301.21% in 2021, and its largest YoY loss of 91936.75% in 2021.
- CRISPR Therapeutics AG's Other Gross PP&E Adjustments (Quarter) stood at -$13.1 million in 2021, then surged by 271.58% to $22.5 million in 2022, then skyrocketed by 46.77% to $33.0 million in 2023, then surged by 81.05% to $59.8 million in 2024, then rose by 14.98% to $68.8 million in 2025.
- Its Other Gross PP&E Adjustments stands at $68.8 million for Q3 2025, versus $65.3 million for Q2 2025 and $62.7 million for Q1 2025.